- Aziyo Biologics Inc AZYO announced that data from the HEAL Study will be presented at the Heart Rhythm Society this Sunday.
- HEAL is a national multi-center study evaluating patients who previously underwent implantation of a cardiac implantable electronic device (CIED) with either an Aziyo CanGaroo Envelope, Medtronic Plc's MDT Tyrx non-biologic envelope, or no envelope, and are returning for a revision procedure at least four months after initial placement.
- The CanGaroo Envelope is made of an acellular biologic matrix designed to promote a natural healing response, resulting in a healthy, vascularized tissue capsule.
- The poster to be presented at HRS 2023 comprises data from 43 patients (CanGaroo, n=11, Tyrx, n=15, or no envelope, n=17) used with their initial CIED implantation.
- Key findings from the interim analysis include:
- Physicians scored CanGaroo reoperations as having 46% easier generator mobilization, 41% easier lead mobilization, and 43% less procedural difficulty than no envelope.
- Lead adhesion classification was scored as significantly less severe in the CanGaroo group compared to no envelope.
- Significantly fewer capsulectomy procedures were required in the CanGaroo vs. Tyrx group (83% less, p=.04).
- Independent, blinded histologic evaluation of pocket biopsies showed 30% thinner capsules in CanGaroo implant pockets vs. no envelope (p=0.12) and 32% thinner capsules vs. Tyrx (p=.09).
- Price Action: AZYO shares are up 4.72% at $2.22 on the last check Friday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
